Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2021-07-13 Earnings Release
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
2021年半年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2021 Half-Year Performance Forecast' for the period January 1 to June 30, 2021. It contains estimated financial performance data, including expected net profit growth and explanations for performance changes. The document explicitly states that the data is unaudited and preliminary, and that detailed data will be disclosed in the 2021 half-year report. The document length is short (930 characters) and it is a forward-looking earnings forecast rather than a full interim report with actual financial statements. Therefore, it is an Earnings Release (ER) type document, which is an initial announcement of quarterly or periodical financial results with key highlights only. H1 2021
2021-07-13 Chinese
独立董事关于公司第七届董事会第十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on a board meeting matter related to a transfer of subsidiary shares for equity incentives and related party transactions. It references company laws, securities laws, and listing rules, and provides an independent opinion on the fairness and compliance of the transaction. The content is focused on board/management decisions and opinions rather than financial results, audit, or regulatory filings. It is not a full annual report, audit report, or earnings release. It is not a notice of voting results or a proxy statement. The document is best classified as Board/Management Information (MANG) because it concerns board meeting matters and independent directors' opinions on corporate governance and transactions.
2021-07-13 Chinese
独立董事对相关事项之事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement of prior approval opinions from independent directors regarding a related party transaction involving equity transfer for employee stock incentives. It references regulatory guidelines and company bylaws, and is signed by independent directors. The content is about governance and board-level approval of a transaction, not a full report or financial statement. It is not an announcement of voting results, nor a full management or audit report. The document is short (504 characters) and focuses on board/management information related to governance and approval of corporate actions. Therefore, the best fitting category is Board/Management Information (MANG).
2021-07-13 Chinese
关于第七届董事会第十一次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution by Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It details the approval of a proposal regarding the transfer of part of the equity of a wholly-owned subsidiary for equity incentives, which constitutes a related party transaction. The document includes voting results and mentions compliance with relevant laws and regulations. It is a formal announcement of a board decision rather than a full management report or financial statement. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a full report or financial disclosure but a specific board resolution announcement.
2021-07-13 Chinese
关于安徽安科生物工程（集团）股份有限公司转让全资子公司部分股权用以股权激励暨关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Guoyuan Securities regarding the verification and opinions on a related-party transaction involving the transfer of part of a wholly-owned subsidiary's equity for employee stock incentives. It includes comprehensive information about the transaction, the parties involved, the equity structure, financial data of the subsidiary, the incentive plan, management and board approvals, and independent directors' opinions. The document is not a simple announcement but a thorough verification and opinion report related to a specific transaction. It does not fit categories like Annual Report, Earnings Release, or Capital/Financing Update directly, but it is a formal audit/verification report related to a corporate transaction and compliance with regulatory requirements. This aligns best with the Audit Report / Information (AR) category, which includes standalone audit reports and results of internal or regulatory checks excluding full annual reports. The document length (6607 characters) and content confirm it is a substantive report, not just an announcement or certification. Therefore, the classification is AR with high confidence. Q2 2021
2021-07-13 Chinese
关于转让全资子公司部分股权用以股权激励暨关联交易的公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement about the transfer of part of a wholly-owned subsidiary's equity for employee stock incentives and related party transactions. It includes comprehensive information about the transaction, the equity structure before and after, financial data of the subsidiary, the incentive plan details, management and board approvals, and independent opinions. The document is not a full financial report but a regulatory announcement about a capital transaction involving share transfer and equity incentives. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is primarily an announcement of a capital change related to share transfer and equity incentives. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length (6456 characters) and detailed content support this classification with high confidence.
2021-07-13 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.